Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

A new approach to disease-modifying drug trials in Parkinson's disease

In English

Författare

  • Roger A. Barker
  • Mark Stacy
  • Patrik Brundin

Summary, in English

Translating new findings in the laboratory into therapies for patients is a slow and expensive process. The development of therapies for neurodegenerative diseases is further complicated by the difficulty in determining whether the drug truly retards the slow degenerative process or provides only symptomatic benefit. In this issue, Aviles-Olmos et al. describe a first in Parkinson's disease (PD) patient study using a drug previously approved for diabetes treatment. In addition to suggesting that the drug may indeed be disease modifying in PD, their innovative approach suggests there may be more rapid and inexpensive avenues for testing novel therapies in PD.

Publiceringsår

2013

Språk

Engelska

Sidor

2364-2365

Publikation/Tidskrift/Serie

Journal of Clinical Investigation

Volym

123

Issue

6

Dokumenttyp

Artikel i tidskrift

Förlag

The American Society for Clinical Investigation

Ämne

  • Neurosciences

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 0021-9738